Remepy Raises $36M for AI-Enhanced Parkinson's Drug

Remepy has successfully closed a $36 million Series A funding round, propelling its total capital raised to $62 million. This significant investment is earmarked to advance its innovative 'Hybrid Drug' platform, with a primary focus on the global Phase III development of Hybridopa, an investigational treatment for Parkinson's disease. The round was spearheaded by prominent venture capital firms O.G. Venture Partners and M Ventures, the strategic investment arm of Merck KGaA, Darmstadt, Germany.

The infusion of capital will also fuel the expansion of Remepy's pharmaceutical co-development partnerships and bolster its proprietary Hybrid Drug pipeline. The company's unique approach redefines therapeutic delivery by integrating prescription pharmaceuticals with personalized, AI-driven digital applications. This novel category of medicine aims to deliver adaptive physical, cognitive, and behavioral interventions alongside traditional drug therapies, all managed through a sophisticated software platform.

This strategic financing positions Remepy to commence the global Phase III trials for Hybridopa, anticipated to begin in the fourth quarter of 2026. The investigational therapy has shown promising results in Phase IIa studies, demonstrating positive impacts on both motor and non-motor symptoms associated with Parkinson's disease. The company is actively preparing for this critical next stage of clinical validation, which will involve extensive international trials.

The Series A round saw robust participation from a distinguished group of existing and new investors, including NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp. This broad investor base underscores strong market confidence in Remepy's pioneering approach to drug development and delivery.

Remepy's Hybrid Drug model is designed not only for patient benefit but also as a valuable development tool for pharmaceutical companies. It offers potential avenues for creating additional intellectual property, supporting drug lifecycle management, and differentiating therapies through integrated, personalized digital support. This dual value proposition is a key driver of the company's strategic co-development initiatives, including a recent collaboration with Merck KGaA, Darmstadt, Germany, targeting rare tumors.

The burgeoning field of digital therapeutics and AI in healthcare is rapidly evolving, with regulatory bodies increasingly adapting to accommodate drug-software combination products. Remepy is strategically positioned to leverage these emerging frameworks. The company's long-term vision involves establishing widespread partnerships across various therapeutic areas, while simultaneously advancing its internal pipeline of innovative treatments.